bumetanide (S95008) / Servier, Neurochlore 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  bumetanide (S95008) / Servier, Neurochlore
    Journal:  A Wholistic View of How Bumetanide Attenuates Autism Spectrum Disorders. (Pubmed Central) -  Aug 22, 2022   
    We suggest that a more holistic view of ASD and other disorders is warranted to account for the multiple sites impacted by the original intra-uterine insult. From this perspective, large-spectrum active repositioned drugs that act centrally and peripherally might constitute a useful approach to treating these disorders.
  • ||||||||||  bumetanide (S95008) / Servier, Neurochlore
    Trial completion date, Trial termination, Trial primary completion date:  Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder. (clinicaltrials.gov) -  Jan 11, 2022   
    P3,  N=211, Terminated, 
    Trial completion date: Sep 2022 --> Oct 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2021 --> Oct 2021; The 6-month efficacy analysis did not show any significant difference between bumetanide versus placebo in the treatment of ASD in the overall studied population. No unexpected safety concerns were identified.
  • ||||||||||  bumetanide (S95008) / Servier, Neurochlore
    Journal:  Phenobarbital, midazolam, bumetanide, and neonatal seizures: The devil is in the details. (Pubmed Central) -  Sep 19, 2021   
    BUM efficiently attenuates autism symptomatology notably in patients with tuberous sclerosis but does not reduce the recurrent seizures, illustrating the uniqueness of epilepsies. Therefore, the efficacy of AEDs to treat babies with encephalopathic seizures will depend on the history and severity of the seizures prior to their administration, challenging a universal common underlying mechanism.
  • ||||||||||  risperidone / Generic mfg.
    [VIRTUAL] The CARS Scale to Assess Pharmacological Therapies in Autism Spectrum Disorder- A Targeted Literature Review () -  Apr 12, 2021 - Abstract #ISPOR2021ISPOR_1066;    
    Together, the studies focused on a total of 9 pharmacological interventions, including secretin, risperidone and bumetanide...CONCLUSIONS The CARS was used in a quarter of the few studies that assessed a pharmacological intervention in ASD. Despite this and the recent recognition by the EMA of the CARS merit in assessing effect on ASD core symptoms, our review indicates the need to define a clinically meaningful treatment response and a MCID for the CARS.
  • ||||||||||  bumetanide (S95008) / Servier, Neurochlore
    [VIRTUAL] Bumetanide Improves Social Behavior in the BTBR Mouse Model of Autism () -  Jul 8, 2020 - Abstract #INSAR2020INSAR_1202;    
    Acute bumetanide administration dose-dependently attenuated the deficit in sociability, an autism-relevant symptom, displayed by BTBR mice. Globally, the present study shows for the first time a postnatal effect of bumetanide in a relevant ASD animal model, supporting its use in clinical trials and suggesting bumetanide as a promising drug to enhance sociability deficits in ASD patients.
  • ||||||||||  bumetanide (S95008) / Servier, Neurochlore
    Trial completion date, Trial primary completion date:  Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder. (clinicaltrials.gov) -  Jul 7, 2020   
    P3,  N=200, Recruiting, 
    Globally, the present study shows for the first time a postnatal effect of bumetanide in a relevant ASD animal model, supporting its use in clinical trials and suggesting bumetanide as a promising drug to enhance sociability deficits in ASD patients. Trial completion date: Apr 2021 --> Apr 2022 | Trial primary completion date: Apr 2021 --> Sep 2021